Brendan Fee leads the firm’s Philadelphia antitrust practice and represents market-leading US and international companies in complex, high-stakes antitrust lawsuits. These disputes often involve alleged price fixing, market allocation, exclusive dealing, monopolization, group boycotts, price discrimination, tying, bundling, standards development, and other alleged violations of federal and state antitrust law.
In the last three years, Brendan has secured nearly a dozen motion to dismiss victories, many of which were affirmed on appeal. His clients are many of the leading companies in diverse industries including pharmaceuticals, technology, healthcare, retail/ecommerce, automotive, energy, and industrial products.
Chambers has identified Brendan as a top antitrust practitioner and describes him as a “very practical, easy-to-work with” lawyer who is “exceptionally smart” and provides clients with “very clear communication” on complex antitrust issues. The Legal 500 has recognized Brendan for his work in civil antitrust litigation, noting that he “is a real star in the making” who “just gets it” when it comes to navigating complicated antitrust questions. In addition, Brendan repeatedly has been named Benchmark Litigation’s 40 & Under “Hot List” and has been included on the Law360 Rising Stars list as one of the top five antitrust lawyers in the US and Europe under the age of 40.
Brendan has written extensively on vertical restraints and pricing, as well as antitrust issues in the life sciences industry. He also speaks regularly on cutting-edge competition issues in the e-commerce sector.
As an adjunct professor of law at Rutgers Law School, Brendan teaches courses on topics such as legal writing and appellate advocacy. He is the litigation practice training partner for Morgan Lewis’s Philadelphia, Princeton, and Wilmington offices. He also participates in the firm’s Class Action Working Group.
Class Action/Multiplaintiff Successes:
In re North Sea Brent Crude Oil Futures Litigation (S.D.N.Y./Second Circuit/US Supreme Court) - Obtained dismissal of Section 1 and 2 Sherman Act claims against Royal Dutch Shell arising out of alleged manipulation of benchmark for North Sea Brent Crude Oil, which was affirmed on appeal by the Second Circuit and the Supreme Court
Philadelphia Taxi Association v. Uber (E.D. Pa/Third Circuit) – Obtained Rule 12 dismissal of Section 2 attempted monopolization claim against Uber arising out of alleged violations of taxi regulations, which was affirmed by the Third Circuit on appeal.
Allen v. Verizon (D.N.J.) – Obtained dismissal of federal antitrust claims against Verizon by a putative class of cell phone purchasers alleging collusion with respect to ESIM standards.
In re K-Dur Antitrust Litigation (D. N.J.) – Served as resolution counsel for Merck in successful settlement of reverse payment class action.
DiMartino v. BMW North America (D. N.J.) – Achieved dismissal on the pleadings of Section 2 putative class action alleging aftermarket tying against BMW.
Gordon v. Travelport (S.D.N.Y.) – Obtained dismissal of damages claims brought by a putative class of indirect purchasers against Travelport alleging collusion among global distribution systems to impose contractual restrictions on airlines.
Torrey v. Cigna Corporation (E.D. Texas) – Secured favorable settlement of federal antitrust and RICO claims against Cigna alleging collusion among health insurers with respect to treatment standards regarding chronic Lyme disease.
Helicopter Helmet Corp. v. Gentex Corp. (D. Del./Third Circuit) – Obtained with prejudice dismissal of Section 1 and Section 2 claims against Gentex arising out of alleged exclusionary conduct in head wear protection market, which was affirmed by the Third Circuit on appeal.
Cable Line v. Comcast (M.D. Pa./Third Circuit) – Obtained dismissal on a Rule 12 motion of allegations of conspiracy to restrain trade in alleged cable installation market, which the Third Circuit later affirmed.
Medical Diagnostic Labs v. Independence Blue Cross (E.D. Pa.) – Secured dismissal of exclusive dealing antitrust claims concerning certain diagnostic tests on a motion to dismiss.
Prescient Medicine Holdings v. Amerihealth Caritas (D. Del.) – Secured Rule 12 dismissal of exclusive dealing claims pertaining to laboratory testing services.
Willow Creek Fuels v. Buckeye Partners (E.D. Pa.) – Obtained dismissal at the pleadings stage of Section 1 and 2 Sherman Act claims, as well as Clayton Act Section 3 exclusive dealing claims brought against Buckeye by a terminated fuel distributor.
Network Visual Services v. ARAMARK Sports and Entertainment (C.D. Cal.) – Obtained Rule 12 dismissal of Section 1 and 2 claims arising out of an alleged exclusive agreement to provide closed circuit advertising services at the Las Vegas Convention Center.
POP Diesel Fuel Systems v. ASTM (D.N.M.) – Obtained denial of a motion for preliminary injunction and complete dismissal of Section 1 Sherman Act claim brought against a standard development organization by a producer of triglyceride fuel.
Caltex Plastics Inc. v. Berry Plastics (C.D. Cal.) – Successfully defended a manufacturer of military specification plastic sheeting against secondary-line Robinson-Patman Act claim.
Advanced Technology Corporation v. ASTM (D. Mass.) – Obtained with prejudice dismissal of a Sherman Act Section 1 claim brought against a standard development organization by a supplier of metal testing equipment.
Deborah Heart & Lung Center v. University of Pennsylvania Health System (D.N.J./Third Circuit) – Successfully resolved claims under Sections 1 and 2 of the Sherman Act against a leading hospital system arising out of supposedly exclusive agreement pertaining to advanced cardiac services.
Distribution/Franchise Law Successes:
Les Bijoux v. Richemont North America (M.D. Fla.) – Obtained stay of Florida Franchise Act claims against supplier of luxury watches and jewelry in favor of arbitration in Switzerland and New York.
Current Representative Cases:
Defending branded pharmaceutical manufacturer against class action antitrust claims arising out of an alleged improper listing of certain patents for the diabetes drug, Actos, in the Orange Book.
Defending generic pharmaceutical supplier in reverse payment antitrust actions pertaining to Zetia.
Defending leading pharmacy benefit manager in antitrust and RICO cases alleging a conspiracy to increase prices on insulin products.
Defending generic pharmaceutical supplier in multidistrict price-fixing cases.
Defending a leading vaccine manufacturer against putative class action alleging Sherman Act Section 2 violations and related state law claims.
Defending technology firm in antitrust class action arising out of allegations of horizontal price fixing with respect to telephone calling services for prison inmates.
Defending top regional health insurance company in class action alleging monopolization claims under Louisiana state law.
Rutgers University School of Law, 2003, J.D., With High Honors
Bloomsburg University of Pennsylvania, 2000, B.A.
US District Court for the Eastern District of Pennsylvania
US District Court for the Middle District of Pennsylvania
US District Court for the District of New Jersey
Awards and Affiliations
Ranked, Antitrust, Pennsylvania, Chambers USA (2018–2021)
Recognized, Competition Future Leader, Global Competition Review's Who's Who Legal (2019, 2020)
Next Generation Lawyer, Antitrust: Civil litigation/class actions: defense, The Legal 500 US (2019–2021)
Member, Practice Group of the Year, Competition, Law360 (2017–2020)
40 & Under Hot List, Benchmark Litigation (2018, 2019)
Recommended, Antitrust - Cartel; Antitrust - Civil litigation/class actions, The Legal 500 US (2017)
Recognized, US News & World Report and Best Lawyers 2017 Practice Group of the Year for Antitrust Law
Rising Star, Irish Legal 100 (2016)
Recognized, Lawyers on the Fast Track, The Legal Intelligencer (2015)
Recognized as a Law360 "Rising Star" in Competition/Antitrust (2014)
Recognized, "Rising Star," Pennsylvania Super Lawyers (2008)
Member, American Bar Association, Antitrust Section